Ponatinib reduces viability, migration, and functionality of human endothelial cells

References

• Valent P, Hadzijusufovic E, Schernthaner GH, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125:901–906.
   PubMed Web of Science ®Google Scholar
• Pasvolsky O, Leader A, Iakobishvili Z, et al. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardio-Oncology. 2015;1:5.
   Google Scholar
• Aprile L, Puccetti L, Galimberti S, et al. Atherothrombotic risk and TKIs treatment in chronic myeloid leukemia patients: a role for genetic predisposition and Pro-inflammatory/pro-oxidative status. Blood. 2013;122:1482.
   Web of Science ®Google Scholar
• Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316–1321.
   PubMed Web of Science ®Google Scholar
• Gora-Tybor J, Medras E, Calbecka M, et al. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma. 2015;56:2309–2314.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796.
   PubMed Web of Science ®Google Scholar
• Nicolini F, Gagnieu M, Heiblig M, et al. Cardio-vascular events occurring on ponatinib in chronic phase chronic myeloid leukemia patients, preliminary analysis of a multicenter cohort. Blood. 2013;122:4020.
   Google Scholar
• Coon EA, Zalewski NL, Hoffman EM, et al. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol. 2013;88:534–535.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Cortes JE, Kantarjian HM, et al. Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with philadelphia chromosome-positive (ph+) leukemias. J Clin Oncol. 2014;32:7078.
   Web of Science ®Google Scholar
• Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128–2137.
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055–4063.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401–412.
   PubMed Web of Science ®Google Scholar
• Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML. Blood. 2013;122:257.
   Web of Science ®Google Scholar
• Katgi A, Sevindik OG, Gokbulut AA, et al. Nilotinib does not alter the secretory functions of carotid artery endothelial cells in a prothrombotic or antithrombotic fashion. Clin Appl Thromb Hemost. 2014;21:678–683.
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967.
   PubMed Web of Science ®Google Scholar
• Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95:952–958.
   PubMed Web of Science ®Google Scholar
• Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med. 2004;8:498–508.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–395.
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–248.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932–936.
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879–894.
   PubMed Web of Science ®Google Scholar
• Tanaka C, Yin OQ, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther. 2010;87:197–203.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research Application Number: 203469orig1s000. Clinical pharmacology and biopharmaceutics review(s) [Internet]; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000ClinPharmR.pdf.
   Google Scholar
• Kim SY, Oh HK, Ha JM, et al. RGD-peptide presents anti-adhesive effect, but not direct pro-apoptotic effect on endothelial progenitor cells. Arch Biochem Biophys. 2007;459:40–49.
   PubMed Web of Science ®Google Scholar
• Felice F, Lucchesi D, di Stefano R, et al. Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells: evidence for differential glutathione peroxidase-1 expression. Microvasc Res. 2010;80:332–338.
   PubMed Web of Science ®Google Scholar
• Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 2006;20:1495–1497.
   PubMed Web of Science ®Google Scholar
• Xu HY, Pan YM, Chen ZW, et al. 12-deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway. J Ethnopharmacol. 2013;146:724–733.
   PubMed Web of Science ®Google Scholar
• Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004;38:1258–1264.
   PubMed Web of Science ®Google Scholar
• Cezar-de-Mello PF, Nascimento-Silva V, Villela CG, et al. Aspirin-triggered lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene. 2006;25:122–129.
   PubMed Web of Science ®Google Scholar
• Yoshihara T, Takahashi-Yanaga F, Shiraishi F, et al. Anti-angiogenic effects of differentiation-inducing factor-1 involving VEGFR-2 expression inhibition independent of the wnt/beta-catenin signaling pathway. Mol Cancer. 2010;9:4598–4599.
   Web of Science ®Google Scholar
• Mohamedali KA, Ran S, Gomez-Manzano C, et al. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer. 2011;11:358–2407. 11-358.
   PubMed Web of Science ®Google Scholar
• Engelmann D, Mayoli-Nussle D, Mayrhofer C, et al. E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B. J Mol Cell Biol. 2013;5:391–403.
   PubMed Web of Science ®Google Scholar
• Wasserstrum Y, Kornowski R, Raanani P, et al. Hypertension in cancer patients treated with anti-angiogenic based regimens. Cardio-Oncology. 2015;1:6.
   Google Scholar
• Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27:4865–4873.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28:2280–2285.
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Morgan CJ, Je Y, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015;94:228–237.
   PubMed Web of Science ®Google Scholar
• Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115:2108–2118.
   PubMed Web of Science ®Google Scholar
• Izumiya Y, Shiojima I, Sato K, et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47:887–893.
   PubMed Web of Science ®Google Scholar
• Schutz FA, Je Y, Richards CJ, et al. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol. 2012;30:871–877.
   PubMed Web of Science ®Google Scholar
• Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568–581.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pacheco FR, Deudero JJ, Castellanos MC, et al. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol. 2006;291:H1395–H1401.
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–1795.
   PubMed Web of Science ®Google Scholar
• Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054–H1058.
   PubMed Web of Science ®Google Scholar
• Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107:1359–1365.
   PubMed Web of Science ®Google Scholar
• Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol. 2005;90:315–326.
   PubMed Web of Science ®Google Scholar
• Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol. 2006;24:1329–1331.
   PubMed Web of Science ®Google Scholar
• Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 2010;56:1131–1136.
   PubMed Web of Science ®Google Scholar
• Li Y, Li S, Zhu Y, et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2014;16:177–185.
   PubMed Web of Science ®Google Scholar
• Eicher C, Dewerth A, Thomale J, et al. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. Br J Cancer. 2013;108:334–341.
   PubMed Web of Science ®Google Scholar
• Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804:445–453.
   PubMed Web of Science ®Google Scholar